Clinical Trials Logo
  1. Home
  2. Social Anxiety Disorder
  3. NCT05600114
  4. Details
NCT05600114 Clinical Trial

Cannabidiol (CBD) for the Treatment of Social Anxiety Disorder

Social Anxiety Disorder Clinical Trial

Official title:
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study, Evaluating the Efficacy, Safety, and Tolerability of Cannabidiol Oral Solution in Subjects With Social Anxiety Disorder

Clinical Trial Details — Status: Active, not recruiting

Administrative data
NCT number NCT05600114
Other study ID # EPI-CBD-001
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date October 27, 2022
Est. completion date December 2023

Study information
Verified date September 2023
Source EmpowerPharm Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A phase 2, multicenter, double-blind, parallel group, placebo-controlled, randomized clinical study, designed to compare the efficacy, safety, and tolerability of 2 dose levels of CBD and a matching placebo for the treatment of subjects with Social Anxiety Disorder (SAD).

Recruitment information / eligibility
Status Active, not recruiting
Enrollment 225
Est. completion date December 2023
Est. primary completion date December 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Clinically predominant diagnosis of Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) SAD - LSAS score of 70 or higher - Females of childbearing potential must test negative for pregnancy and agree to use a reliable birth control method. Male subjects must also agree to use highly effective methods of contraception. - Read, understand, and sign the informed consent form. - No significant physical health abnormalities based on physical exam, ECG and laboratory tests. Exclusion Criteria: - Other current psychiatric disorder as the clinically predominant diagnosis. - Lifetime diagnosis of schizophrenia or any other psychosis, MDD with psychotic features, intellectual disability, autism spectrum disorders, bipolar disorder type 1, and cannabis use disorder - Previous 6 months diagnosis of Post-traumatic stress disorder, obsessive compulsive disorder, moderate to severe alcohol use disorder, and substance abuse disorder (except tobacco use disorder or mild alcohol use disorder) - Severe MDD - Use of oral psychoactive medications or beta adrenergic antagonists in the past 4 weeks, or depot neuroleptics within 12 weeks - Electroconvulsive therapy within 6 months, psychotherapy or transcranial magnetic stimulation within 3 months - Clinically significant abnormality or clinically significant unstable medical condition - Impaired liver function - Significant risk of suicide or homicide - Pregnancy/lactation - Sensitivity to CBD or excipients - Current cannabis use; past frequent cannabis use - Illegal drug use

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• Cannabidiol oral solution
CBD 150 mg BID
• Cannabidiol oral solution
CBD 300 mg BID
• Placebo
Placebo BID

Locations
Country Name City State
United States EPI-CBD-001 Site Bellevue Washington
United States EPI-CBD-001 Site Cedarhurst New York
United States EPI-CBD-001 Site Chicago Illinois
United States EPI-CBD-001 Site Encino California
United States EPI-CBD-001 Site Jacksonville Florida
United States EPI-CBD-001 Site Lauderhill Florida
United States EPI-CBD-001 Site Lemon Grove California
United States EPI-CBD-001 Site Los Alamitos California
United States EPI-CBD-001 Site Maitland Florida
United States EPI-CBD-001-Site New York New York
United States EPI-CBD-001-Site Oceanside California
United States EPI-CBD-001 Site Oklahoma City Oklahoma
United States EPI-CBD-001 Site Orlando Florida
United States EPI-CBD-001 Site Portland Oregon
United States EPI-CBD-001-Site Rochester New York
United States EPI-CBD-001 site San Jose California
United States EPI-CBD-001 site Wichita Falls Texas

Sponsors (1)
Lead Sponsor Collaborator
EmpowerPharm Inc.

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary Mean change from baseline to endpoint in the Liebowitz Social Anxiety Scale (LSAS) 10 weeks
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06274112 - Using TMS to Understand Neural Processes of Social Motivation N/A
Completed NCT02554929 - Treatment of Social Anxiety Disorder and Selective Mutism N/A
Completed NCT00684541 - Interpretation Modification Program for Social Phobia N/A
Completed NCT00684320 - Attention Disengagement Training for Social Phobia N/A
Completed NCT03247075 - Internet-delivered CBT vs Internet-delivered Support and Counseling for Youth With Social Anxiety Disorder - An RCT N/A
Completed NCT02811458 - Clinical Trial of Transdiagnostic Cognitive-Behavior Therapy for Anxiety Disorders N/A
Withdrawn NCT04622930 - Waitlist-Control Trial of Smartphone CBT for Social Anxiety Disorder (SAD) N/A
Active, not recruiting NCT05018312 - Modified Collaborative Assessment VS Standard Assessment on Readiness For Psychotherapy Among Patients With Anxiety N/A
Active, not recruiting NCT05124639 - Clinical Trial of a Group Self-management Support Program for Anxiety Disorders N/A
Completed NCT05858294 - The Safety, Acceptability and Efficacy of Alena N/A
Not yet recruiting NCT06081348 - Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders Phase 2
Not yet recruiting NCT02924610 - Brief Intervention to Reduce Fear Phase 4
Active, not recruiting NCT02592564 - Brain Plasticity and Cellular Aging After Internet-delivered CBT for Social Anxiety Disorder N/A
Recruiting NCT02305537 - Building an Outcomes Assessment Infrastructure to Assess Anxiety Treatment N/A
Terminated NCT03764644 - Web-based Attention Bias Modification Treatment for Childhood Anxiety Disorders N/A
Unknown status NCT01712321 - Study of Vilazodone to Treat Social Anxiety Disorder N/A
Completed NCT01320800 - CBT for Social Anxiety Disorder Delivered by School Counselors Phase 2
Completed NCT00773162 - Flushing in Social Anxiety Disorder on Seroquel Phase 3
Completed NCT00485888 - Flushing in Social Anxiety Disorder on Cipralex Phase 2
Completed NCT00485615 - An Open Label Trial of Omega 3(o3mega+Joy)in the Treatment of Social Phobia Phase 2